Adverse events636

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 636

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	MMB 200 mg QD + Placebo- Randomized Double-Blind Treatment Period	12	130	34
other	Anaemia	Blood and lymphatic system disorders	DAN 300 mg BID + Placebo- Randomized Double-Blind Treatment Period	6	65	11
other	Anaemia	Blood and lymphatic system disorders	MMB 200 mg QD- Open-Label Extended Treatment Period	9	93	18
other	Anaemia	Blood and lymphatic system disorders	DAN 300 mg BID to MMB 200 mg QD- Open-Label Extended Treatment Period	3	41	6
other	Neutropenia	Blood and lymphatic system disorders	MMB 200 mg QD + Placebo- Randomized Double-Blind Treatment Period	7	130	11
other	Neutropenia	Blood and lymphatic system disorders	DAN 300 mg BID + Placebo- Randomized Double-Blind Treatment Period	2	65	5
other	Neutropenia	Blood and lymphatic system disorders	MMB 200 mg QD- Open-Label Extended Treatment Period	5	93	9
other	Neutropenia	Blood and lymphatic system disorders	DAN 300 mg BID to MMB 200 mg QD- Open-Label Extended Treatment Period	2	41	2
other	Thrombocytopenia	Blood and lymphatic system disorders	MMB 200 mg QD + Placebo- Randomized Double-Blind Treatment Period	28	130	50
other	Thrombocytopenia	Blood and lymphatic system disorders	DAN 300 mg BID + Placebo- Randomized Double-Blind Treatment Period	7	65	11
other	Thrombocytopenia	Blood and lymphatic system disorders	MMB 200 mg QD- Open-Label Extended Treatment Period	13	93	22
other	Thrombocytopenia	Blood and lymphatic system disorders	DAN 300 mg BID to MMB 200 mg QD- Open-Label Extended Treatment Period	7	41	10
other	Abdominal pain	Gastrointestinal disorders	MMB 200 mg QD + Placebo- Randomized Double-Blind Treatment Period	10	130	12
other	Abdominal pain	Gastrointestinal disorders	DAN 300 mg BID + Placebo- Randomized Double-Blind Treatment Period	6	65	6
other	Abdominal pain	Gastrointestinal disorders	MMB 200 mg QD- Open-Label Extended Treatment Period	3	93	3
other	Abdominal pain	Gastrointestinal disorders	DAN 300 mg BID to MMB 200 mg QD- Open-Label Extended Treatment Period	1	41	2
other	Abdominal pain upper	Gastrointestinal disorders	MMB 200 mg QD + Placebo- Randomized Double-Blind Treatment Period	3	130	3
other	Abdominal pain upper	Gastrointestinal disorders	DAN 300 mg BID + Placebo- Randomized Double-Blind Treatment Period	5	65	6
other	Abdominal pain upper	Gastrointestinal disorders	MMB 200 mg QD- Open-Label Extended Treatment Period	2	93	3
other	Abdominal pain upper	Gastrointestinal disorders	DAN 300 mg BID to MMB 200 mg QD- Open-Label Extended Treatment Period	1	41	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04173494/events

API reference For AI assistants

Adverse events636

Sources 3

Read this list from software.